Skip to content

Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness

Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness at Day 1 and Day 8 Post Op

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07222150
Enrollment
105
Registered
2025-10-29
Start date
2025-10-07
Completion date
2026-10-31
Last updated
2025-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

Cataract Surgery, Phacoemulsification

Brief summary

Phacoemulsification (cataract surgery) is usually performed while temporarily increasing the pressure inside the eye. The purpose of this study is to see if maintaining different pressure levels inside the eye during this procedure results in fewer side effects and better vision shortly after the surgery. Cataract surgery will be performed using Unity VCS at a lower IOP in one eye compared to traditional IOP with Centurion Vision System with Ozil in the other eye. Both of which are approved by the United States Food and Drug Administration (FDA) and used per label.

Detailed description

Study patients will undergo sequential bilateral cataract surgery with the same cataract grade in both eyes. Both surgeries will be completed within one week of each other. The first surgical eye will be randomly assigned (like the flip of a coin). Study patients will have surgery performed with the Alcon Unity VCS system using 4D. The second eye will undergo surgery a week later with Alcon Centurion Vision System (VCS) with Ozil. Surgery with the Unity VCS arm will be performed with a lower IOP setting (less than 40). Surgery with the Centurion with Ozil arm will be performed with a higher IOP setting (greater or equal 60). Participation in the study is expected to take one month.

Interventions

DEVICECataract surgery with Unity VCS

Standard cataract surgery

DEVICECataract surgery with Centurion with Ozil

Standard cataract surgery

Sponsors

Alcon, a Novartis Company
CollaboratorINDUSTRY
Metrolina Eye Associates, PLLC
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective, two-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Unity VCS 4D phaco with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 65mmHg (high IOP) in the other eye usingCenturion Vision System with Ozil.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cataracts

Exclusion criteria

* Glaucoma, cornea disease

Design outcomes

Primary

MeasureTime frameDescription
Central corneal thickness (CCT)Pre-operative, Post-operative day #1, Post-operative day #8 for each arm of the studyMeasurement of post-operative CCT pre and post-operatively with Pentacam

Countries

United States

Contacts

Primary ContactIVAN MAC, MD
imac@metrolinaeye.com7042341930
Backup ContactMegan Lee
mlee@metrolinaeye.com7042341930

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026